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1.1 Huntington Disease 
 
1.1.1 Historical overview 
 
The disease known today with the name “Huntington Disease” (HD) was 
described for the first time by George Huntington. He was an American 
physician who wrote at the age of 22 a paper entitled “On Chorea” published 
on the journal “Medical and Surgical Reporter” of Philadelphia on April 13, 
1872 were he properly described HD as hereditary disease characterized by 
unwanted choreatic movements, behavioral and psychiatric disturbances and 
dementia.   
In 1964 Blinderman, Weidner & Markham (Kenneth et al., 1973) discovered 
that HD is an autosomal dominant progressive neurodegenerative disorder 
where a selective neural cell loss take place with a consequent atrophy in the 
caudate nucleus and putamen. 
In 1983 Gusella et al.  mapped Huntingtin (HTT) in the chromosome 4 (it was 
the first disease-associated gene that was molecularly mapped to a 
human chromosome) (Gusella et al., 1983). Ten years later, scientists of the 
Huntington's Disease Collaborative Research Group (HDCRG) identified the 
gene carrying the mutation, the IT15 gene that coding for a big protein that 
now is known as Huntingtin (HTT). Moreover, they determined the precise 
nature of the HD-associated mutation in HTT (MacDonald et al., 1993) and 
discover that the HTT gene contains a region where the triplet nucleotide CAG 
is repeated several times and that is longer in the individuals carrying the 
disease with respect to the unaffected ones.  
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1.1.2 The HTT gene. 
 
The only agent causing HD is a mutation that brings to a trinucleotide CAG 
repeat expansion in the HTT gene that encodes for a 3,144-residue protein with 
a molecular mass of ~350 kD. Progressive motor disability, depression, 
personality changes, progressive decline in cognitive capabilities together with 
a related family history are the most common symptoms that bring clinicians 
to the diagnosis of the HD. However, to confirm the diagnosis of HD a genetic 
test to determine the number of CAG repeats in exon 1 of HTT (HD) gene is 
mandatory (Craufurd et al., 2015). This mutation is translated in a 
polyglutamine stretch in the huntingtin (HTT) protein. HD follows the 
autosomal dominant inheritance pattern. A parent has 50% chance of passing 
the mutated gene to the child. Inheriting a single mutated allele is enough to 














Figure 1.1 Huntingtin gene scheme: The huntingtin gene is located on the 
short arm of chromosome 4; encodes a protein of 3144 amino acids, one 
of the largest in the human genome. HD results from a polyglutamine 
expansion in exon one of this gene. 
3 
 
Classifying the HD alleles is still controversial but most of the researchers 
agree to classify the alleles as follow: normal alleles with 26 or less CAG 
repeats (no risk of developing the HD); reduced-penetrance HD alleles with 
36-39 CAG repeats (these alleles confer to the carrier a high risk of developing 
the disease; asymptomatic individuals in old age with CAG repeats in this 
range have been identified) (Langbehn et al., 2004); full-penetrance HD alleles 
with 40 or more CAG repeats (the individuals carrying these alleles will 
develop the HD). Intermediate alleles with 27-35 CAG repeats (fig.1.1) (not at 
risk of developing symptoms of HD, but because of the instability in the CAG 
tract, may be at risk of having a child with an allele in the HD-causing range) 
(Semaka and Hayden, 2014)  
Homozygous HD patients are rare, and there is still controversy over whether 
homozygosity for the mutation in HD is associated with a more severe 
phenotype. Reports from sporadic cases in which both parents are affected 
showed that the age-at-onset, progression and severity of the disease are 
similar in homozygotes and heterozygotes (Alonso et al., 2002; Dürr et al., 
1999). However, this conclusion was based on clinical evaluation of eight 
potential homozygous and only two confirmed cases, and did not take into 
account differences in CAG tract sizes between siblings, or other possible 
genetic modifiers. A more recent detailed comparison between a large 
homozygous patients’ series and their heterozygous counterparts in a 
multicenter study revealed significant clinical and neuropathological 
differences between the two groups (Squitieri et al., 2003). The fact that HD is 
more severe in homozygosity is supported even by works involving cell lines 
derived from heterozygous and homozygous HD patients (Squitieri et al., 
2010; Mormone et al., 2006) and analyses of mouse models for HD (Graham 
et al., 2006). HD is not the only disease caused by a CAG expansion. There 
are at least other eight diseases, presenting a dominant pattern of inheritance 
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and neuronal degeneration, with a polyglutamine stretch in different proteins 
that share nothing with each other in homology or sequence similarity. This is 
a strong prove that HD, like all other polyglutamine disorders, is caused by a 
gain-of-function mechanism and that the expanded polyglutamine stretch is 
responsible for the pathogenesis (Reiner et al., 2011).   
 
1.1.3 HD Neuropathology  
 
Normal huntingtin is important for adult neuronal function and it is critical in 
early embryonic development, before the emergence of the nervous system 
(Cattaneo et al., 2005; Nasir et al., 1995). Cell lines from heterozygote HD 
patients showed expression of both normal and mutant huntingtin and the wide 
expression of the HTT transcript does not correlate with the pattern of 
neuropathology in the disease. Since 1993 many molecular events that 
precipitate the disease have been described. However, the role of the huntingtin 
(wtHTT) in healthy individuals and how the mutated huntingtin brings to the 
illness remain still unclear. Immunocytochemistry indicated that huntingtin is 
located in neurons throughout the brain, with the highest levels evident in 
larger neurons (Gutekunst et al., 1995). The pathology of the disease has been 
attributed to toxic gain of functions for the mutant huntingtin protein, such as 
protein aggregation, transcriptional dysregulation, defective energy 
metabolism, oxidative stress, excitotoxicity, and inflammation (fig. 1.2) 
(Andre et al., 2016). The mutant huntingtin (mHTT) has the propensity to 
misfold and aggregate, producing cellular aggregates and intranuclear 
inclusions (Scherzinger et al., 1997; Gutekunst et al., 1999).  Cytoplasmic 
aggregations interfered with nucleocytoplasmic protein and RNA transport 
































Figure 1.2 Huntington disease (HD) pathway Mutant Htt (mHtt) has effects 
both in the cytoplasm and in the nucleus. In the cytoplasm, mHtt can interfere 
with BDNF vesicular transport on microtubules can affect Ca2+ signaling 
stimulating NMDAR activity, destabilizing mitochondrial Ca2+ handling 
and leads to mitochondrial dysfunction. The mHtt translocates to the 
nucleus, where it forms intranuclear inclusions. Nuclear toxicity is believed  
to be caused by interference with gene transcription, leading to loss of 
transcription. (From KEEG pathway Database). 
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On the other hand, HTT aggregates, are much more common in the cerebral 
cortex than in the striatum. It is known that in HD there is a low cortical 
neuronal loss and a significant striatal neuronal loss. Also among the neuronal 
populations in the striatum, aggregates occurred predominantly in interneurons 
instead of in the more vulnerable medium spiny projection neurons (Gutekunst 
et al., 1999; Kuemmerle et al., 1999). Furthermore, inclusion bodies (IB) 
formation reduced the levels of diffuse mutant HTT and the risk of striatal 
neuronal death in a primary striatal neuronal model of HD (Miller et al., 2010). 
Even in a mouse model expressing an N-terminal human HTT fragment (exons 
1 and 2) with 120Qs with frequent and widespread IB formation there were no 
evidence of neuronal dysfunction or neurodegeneration (Slow et al., 2005). All 
these findings suggest instead that are the soluble protein fragments, not 
insoluble aggregated proteins, which cause toxicity in these disorders (Slow et 
al., 2006). Recent studies have shown that oxidative stress is a key player in 
the pathogenesis of HD. Classical studies from postmortem brains of HD 
patients have demonstrated a significant increase in the level of oxidative 
damage (Stack et al., 2008).  
There is a significant increase in lipid and decrease in glutathione levels in the 
plasma of symptomatic patients compared to that of healthy subjects. The same 
thing was seen when comparing levels of lipid peroxidation in the plasma of 
asymptomatic HD gene carriers with age and sex matched healthy subjects 
(Klepac et al., 2007; Christifides et al., 2006). The increased amounts of redox 
species in the plasma are probably due to the deregulation of brain energy 





1.1.4 Brain energy metabolism failure in HD 
 
HD is characterized by a failure in brain energy metabolism. HD brain shows 
an impairment in glucose transportation, reduced glycolysis, decreased lactate 
concentration, altered levels of TCA cycle enzymes and diminished oxidative 
phosphorylation (Naseri et al., 2015; Powers et al., 2007; Squitieri and 
Ciarmello, 2010; Milakovic and Johnson, 2005). Evidences of glucose hypo-
metabolism are reported in literature. There are many evidences indicating that 
the energetic metabolism impairment in HD patients is given by defective brain 
glucose uptake, especially in neurons (Morea et al., 2017).  In membranes of 
post-mortem samples of caudate and cortex brain regions the quantity of 
GLUT1 and GLUT3 was significantly reduced in advanced HD stages patients 
with respect to non-HD controls. Instead at earlier stages, there was no 
significant difference in GLUT1 and GLUT3 membrane concentration 
compared with non-diseased controls (Gamberino and Brennan, 1994).  
 
1.1.5 Ca(II) metabolism impairment in HD patient 
 
HTT has also been shown to interact with a protein located in the ER 
membrane, the Inositol-1,4,5-triphosphate receptor (IP3R). In several cellular 
HD models, the Ca2+ regulating pathways have been found defective, in fact 
mutant HTT (but not the wild type protein) increases the Ca2+ releasing activity 
of the IP3 receptor rendering the neuronal cells more vulnerable to the stress 
induced by Ca2+ and could contribute to mitochondrial Ca2+ overload (Tang et 
al., 2003; Giacomelli et al., 2011). One of the proposals trying to explain the 
molecular basis of HD put at the center of the attention the mitochondrial stress 
caused by a dysregulation of the system for the neuronal homeostasis of Ca2+. 
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Mitochondrial calcium abnormalities occur early in HD pathogenesis and may 
be a direct effect of mutant huntingtin on the organelle (Panov et al., 2002). 
Disrupted mitochondrial calcium homeostasis potentiates NMDA receptors 
which causes calcium influx. Calcium overload may trigger apoptosis in 
medium spiny striatal neurons in HD (Bezprozvanny and Hayden 2004). 
Mutant huntingtin causes the increased levels of reactive oxygen species 
(ROS) in neuronal and nonneuronal cells which directly contributes to cell 
death (Wyttenbach et al., 2002). Mutant HTT leads to mitochondrial 
dysfunction causing increased neurodegeneration of striatal neurons and motor 
abnormalities. (Greenamyre et al., 2007; Sassone et al., 2015). Mitochondrial 
dysfunction is considered to be one of the key defects in HD pathogenesis. 
Activities of complexes II, III, and IV are significantly reduced in the striatum 
of HD patient (Brennan et al., 1985; Stahl et al., 1974; Gu et al., 1996). 
 
1.1.6 Autophagy in HD 
 
Ubiquitin-proteasome system dysfunction is a consistent feature of HD 
pathology and HD is linked to global changes in the ubiquitin system.  
(Bennet et al., 2007) There are many findings suggesting that autophagy plays 
a critical role in the degradation of N-terminal HTT and altered processing of 
mutant HTT by autophagy may contribute to HD pathogenesis. (Qin et al., 
2003; Ravikumar et al., 2002) Recently a possible mechanism of the altered 
autophagy in HD was described. Polyglutamine domain enables wild-type 
ataxin 3 to interact with beclin 1, a key initiator of autophagy. This interaction 
allows the deubiquitinase activity of ataxin 3 to protect beclin 1 from 
proteasome-mediated degradation and thereby enables autophagy (Ashkenazi 
et al., 2017).  
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Later in life when proteasomal function becomes compromised, the autophagic 
pathway become of crucial importance. Interestingly, the striatal-selective 
pathology of HD may reflect the interaction between mHTT and the striatal-
selective G-protein, Rhes protein of unclear function that has a preferential 
expression in the striatum. Rhes binds mHTT and acts as a SUMO 
(Small Ubiquitin-like MOdifier) E3 ligase to stimulate sumoylation of mHTT, 
a post-translation modification known to augment the mHTT solubility and 
therefore its toxicity. Rhes can activate autophagy by competitively displacing 
the inhibitory binding of Bcl-2 to Beclin-1. Thus, the sequestration of Rhes by 
mHTT with aging may bring to a diminished autophagic flux (Mealer et al., 
2014). 
 
1.1.7 Clinical features of HD 
 
Brain abnormalities in HD are developed before evident symptoms, and 
involve the entire brain to a greater or lesser extent, resulting in about 25% of 
brain weight loss in advanced HD (Halliday et al., 1998). Numerous studies in 
recent years have used brain imaging technologies to elucidate the 
pathogenesis and progress of HD. Neuroimaging like MRI, CT and PET have 
revealed significant striatal atrophy as many as 11 years prior to clinical onset 
of the disease (Aylward et al., 2004). A selective degeneration of neurons in 
the caudate and putamen explain the most of the neuropathologic features of 
HD (fig. 1.3). As striatal degeneration progresses, degenerative changes occur 
to other brain regions connected to the striatum, in particular, the globus 
pallidus, the subthalamus, and the cerebral cortex and the preferential 
degeneration of medium spiny neurons provides the neurobiologic basis for 

























The classic signs of HD are progressive chorea, rigidity, dementia, psychotic 
and behavioral impairment. Generally, individuals that carry a mutated HTT 
allele will have a pre-symptomatic phase with a healthy life, free of clinical 
symptoms. Before the clinical manifestation of HD, a prodromal phase with 
minor changes in one or more of the following occurs: motor skills, cognition, 
depression and psychiatric disturbances (Bates et al., 2002). The mean age of 
onset for HD is 35 to 44 years, nearly in one fourth of the HD population, the 
Figure 1.3 Brain Atrophy (HD).  Frontal section through the right basal 
forebrain of a (A)representative control individual (B)clinically 
diagnosed and genetically confirmed HD patient. Note the loss of deep 
white matter (1), the narrowed corpus callosum (CC) (2) and widened 
third ventricle (3). The atrophy of the caudate nucleus (C) (4) and 
putamen (PU) (5) AC, anterior commissure; PA, pallidum; PU, putamen. 
(From Rub et al., 2009). 
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onset is delayed until after age 50 years, a few even after 70 years of age. The 
survival time after onset goes from 5 to more than 25 years (usually 15 to 18 
years). The average age at death is 54 to 55 years (Harper 2005). In late stages 
of HD, motor disability becomes severe with disturbances of both involuntary 
and voluntary movements. Patients show serious weight loss and are unable to 
move, speak, swallow or take care of their own hygienic needs (Warby et al., 
2014). A global and progressive decline in cognitive capabilities have been 
identified even before the onset of motor symptoms (Rupp et al., 2010). 
Individuals with HD develop significant personality changes, but the 
psychiatric changes tend not to progress with disease severity (Anderson & 
Marder 2001; Rosenblatt, 2007). Depression is more common in persons with 
HD compared to the general population with a higher suicide risk before 
receiving the diagnosis and when the disease advance to the point that patients 
are not fully independent to take care for oneself (Baliko et al., 2004, Paulsen 
et al., 2005). 
 
1.1.8 Juvenile HD  
 
As an accepted definition since 1968, Juvenile onset Huntington disease (JHD) 
include cases with onset at 20 years of age or earlier. (Bruyn 1968). The first 
clear description of juvenile HD (JHD), is attributed to Hoffmann in 1888.  In 
this article, he described a family with HD and two female cousins who 
developed chorea in school age (Hoffmann 1888). Individuals with CAG repeat 
length >60, with few exceptions, have juvenile onset of the Huntington Disease 
(fig1.4) (Telenius et al., 1993). Only about 5% to 7% of individuals with HD 
experience the onset of symptoms before age 21 (Nance and Myers 2001). In 
the majority of JHD cases the transmitting parent is the father. This occurs in 
approximately 70–80% of the cases with an onset between 11 and 20 years of 
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age and may be over 90% in those with childhood-onset HD (Oliver et al., 
2013). This is probably due to the instability in the CAG repeat length during 
















There is similarity between the pathology seen in HD and JHD although the 
juvenile onset of the disease seems to be more severe. In an early stage, JHD 
patients will experience bradykinesia, dystonia and parkinsonian features, 
while chorea, if present, is less prominent. On the contrary, classically, patients 
with adult HD, will demonstrate signs of chorea at the beginning of the disease, 
while bradykinesia and dystonia are going to be evident with the progression 
of the disease (Oliver et al., 2013). 
 
 
Figure 1.4. HD repeat size and onset age. The relationship between the 
repeat size and the age at onset is presented. Persons with repeats of 60 
or larger commonly have very young onset, before the age of 20, and 
among these large repeats there is a clear relationship between repeat size 
and onset age. (From Myers 2004). 
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1.1.9 Demographics of HD 
 
HD is more common in the Caucasian population with a prevalence of 5-10 
per 100,000, and a much lower prevalence in Asian and African 
populations. The prevalence of HD exceeds 15 per 100,000 in some 
populations, mostly of western European origin (Bates et al., 2002). About 
6500 subjects are currently affected by HD in Italy and this number is prone to 
further increase in the next decades because of population aging, variable 
phenotype penetrance and improved life expectancy (Squitieri et al., 2015). 
These are huge numbers for a devastating disease but what is even more 
concerning is that approximately 1-4% of the general population is found to 
have intermediate HTT alleles, who are at risk of having a child with an allele 
in the HD-causing range (Semaka et al., 2010). Considering all the features of 
the disease more resources should be directed to the research and to the 
institutions dealing with HD patients 
 
1.1.10 Treatment of HD 
 
Although in these decades a number of disease pathways have been identified 
as potential therapeutic targets, there is currently no treatment known to slow 
the worsening of HD progression (Banno et al., 2017). To date therapies are 
limited to the clinical symptoms of the disease: chorea, impaired voluntary 
movement, behavioral changes and dementia (Frank, 2014). Recent guide 
lines suggest that the treatment of chorea is not necessary in most of the cases 
and that patients may have a better quality of life when they use no drugs to 
control the involuntary movements. In the cases when the chorea requires 
treatment the clinicians may recommend tetrabenazine (TBZ), amantadine, or 
riluzole (Armstrong and Miyasaki 2012). There is a wide variety of behavioral 
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and psychiatric issues that may be seen in HD. Valproate and olanzapine, given 
at the lowest effective doses, may be helpful for relieving both psychiatric and 
behavioral disorders in patients with HD (Grove et al., 2000). Management 
outside of pharmacotherapy should be considered when possible. Creatine 
given daily as a supplement has been shown to retard the rate of progression 
of HD (Tabrizi et al., 2003). A good diet and a regular program of physical, 
mental, and social stimulation is beneficial for every human to improve some 
of the symptoms and “halt Huntington’s progression” (Dawes et al., 2015). 
 
1.2 Induced pluripotent stem cells: a new source of stem cells to 
model rare diseases. 
 
1.2.1 What are stem cells? 
 
A stem cell is defined as an unspecialized cell capable of self-renewing through 
cell division and able to give rise to differentiated cells with specialized 
functions (Pera et al., 2000). 
Stem cells can be categorized, depending upon their differentiation potential, 
(Odorico et al., 2001) as: 
1. totipotent cells, that have total potential, with the ability to differentiate 
not only in any cell type of the organism but also into extra-embryonic tissues; 
2. pluripotent cells, a specialized kind of totipotent cells that can give rise 
only to tissues derived from the embryonic inner cell mass 
3. multipotent cells, more specialized stem cells that are committed to 
give rise to cells that have a particular function (i.e. hematopoietic stem cells) 






Figure 1.5 General hierarchy for the stem cell niche a) Totipotent cells, 
deriving from zygote. This cells have the potential to give rise to all of 
embryonic and extra-embryonic cells and tissue; b) Pluripotent cells, deriving 
from the inner cell mass (ICM) of an embryo. can form all somatic and 
germline cells of a rising organism; c) Multipotent cells can only give rise to 
cells of their lineage. Most adult stem cells are multipotent (from Ramakrishna 
et al 2011). 
 
1.2.2 Human embryonic stem cells 
 
Human pluripotent stem cells (hPSCs),  including human embryonic stem cells 
and human induced pluripotent stem cells, must respect four criteria: 1)  they 
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must origin from a pluripotent cell population 2) they must be capable of self-
renewal indefinitely in the undifferentiated state 3) they must be capable of 
maintaining normal karyotype during growth 4) their transplantation into 
immune-deficient mice must lead to the formation of differentiated tumors 
comprising all three germ layers, resembling spontaneous human teratomas. 
hESCs are able to give rise to all of the somatic and germ line cells of the fully 
developed organism, these cells are the "uncommitted" progenitors of the 
subsequent three embryonic germ layers: ectoderm, endoderm, and mesoderm 
(Surani, 2001; Lovell-Badge, 2001). In 1998, it was described the first 
successful human Embryonic Stem cell isolation, derived from the inner cell 
mass of a blastocyst during gastrulation (Thomson et al., 1998; Donovan and 
Gearhart, 2001). The use of human embryos to obtain the inner cell mass 
raised ethical concern and limitation (Strong et al., 2009; Johnson, 2008). For 
these reasons, effort was done to be able to obtain pluripotent stem cells 
without the embryos use. Chung et al. successfully derived human ESC 
lines from a single blastomere biopsied from patient embryos as is 
routinely done during preimplantation genetic test (Chung et. al, 2008). 
However, there is a variable efficiency of producing human ESC’s line 
from individual blastomeres, this depends on properties of the isolated 
blastomere and the embryonic cell stage of isolation but also from the 
particular culture conditions to retain the totipotency of the i solated 
blastomere (Desai et al., 2015). 
 
1.2.3 Human induced pluripotent cells 
 
As already mentioned, hPSCs include also human induced pluripotent 
cells (hiPSCs). In 2006, Takahashi and Yamanaka demonstrated a 
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revolutionary technology able to take somatic cells back to an 
indifferentiated condition. 
In that work 24 genes were selected as candidates for factors that induce 
pluripotency. They concluded that by combining just four transcription factors: 
octamer 3/4 (Oct3/4), SRY box– containing gene 2 (Sox2), Kruppel-like factor 
4 (Klf4), and c-Myc was sufficient to generate pluripotent cells, which were 
called induced pluripotent stem (iPS) cells, directly from mouse embryonic or 
adult fibroblast cultures (Takahashi and Yamanaka, 2006).  Only a few months 
later, human fibroblasts were reprogramed to iPSC’s by introducing the human 
orthologs of the four pluripotency-associated transcription factors from the 
same group (Takahashi et al., 2007). The iPS cells so obtained shared the main 
characteristics of embryo-derived stem cells, were similar in morphology, 
growth properties, expression of pluripotency markers and were also able of 
self-renewal and to differentiate into cells of the three germ layers (Takahashi 
et al., 2007; Takahashi & Yamanaka, 2006). Takahashi and Yamanaka used 
retroviral vectors for the delivery of the reprogramming vectors. This protocol 
was based on insertion of foreign DNA into the reprogrammed genome with a 
high concern of insertional mutagenesis (Hu, 2014). Even the reactivation and 
residual expression of the randomly integrated reprogramming factors which 
are tumorigenic can become a serious limitation with c-Myc found to be 
responsible for the tumors found in iPSC chimeric mice (Nakagawa et al., 
2008). For these reasons integrating vectors are not the best choice in the 
generation of iPSC’s for disease modeling or even less in cell therapy where 
safety is the biggest concern. 
In order to reduce or eliminate transgene integration almost all of the gene 
delivery systems have been employed in factor reprograming and many of 
these techniques perform direct reprogramming without integration (Hu et al., 
2014): 1) Adenoviral reprograming with transgene dilution over time due to 
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cell division (Stadtfeld et al., 2008); 2) PiggyBac (PB) transposition system 
(Woltjen et al., 2009); 3) Direct delivery of reprograming proteins; (Kim et al., 
2009) 4) Direct delivery of reprogramming RNA (synthetic mRNA, RNA 
virus, RNA replicon, or miRNA) (Warren et al., 2010; Fusaki et al., 2009; 
Yoshioka et al., 2013; Miyoshi et al., 2011). 
 
1.2.4 Stem Cells for Modeling Human Disease 
 
Animal models and immortalized cell systems are widely used as models of 
human diseases mechanisms and therapeutic development. Human conditions 
are not always reflected in animal models because of species differences and 
artificially manipulated cells did not represent the best choice in disease 
modeling. In fact, 95% of new drugs tested in artificially manipulated cells 
were withdrawn due to off-target effects (Munos, 2009). 
Human tissues and many primary cell types harvested from healthy donors or 
patients with a relevant genetic condition could be a more reliable model. 
However, the difficulty to obtain fresh human disease samples is clear, 
especially samples able to model rare cardiovascular and neurodegenerative 
diseases because of limited number of suitable donors with a genetic 
background. What is even more limiting, most of the human samples from the 
heart or the brain are obtained from the end stages of the disease or 
postmortem. Thus, it becomes impossible to critically observe the development 
of pathological feature and only a few number of scientists would have the 
possibility to manipulate that kind of samples. 
For these reasons, human pluripotent stem cells can become the principal actor 
in genetic disease modeling. Quantitative phenotyping on hiPSC-based models 
of neurodegenerative diseases provides a clear profile of these cells with severe 
defects in growth, migration and function compared to healthy controls. These 
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distinct phenotypes can offer a great help in diseases modeling and developing 




2. Aim of the study 
 
Since the discovery of the HTT mutation 24 years ago, more than 15,000 
papers have been published on HD. However, both the role of the huntingtin 
(wtHTT) in healthy individuals and the molecular mechanisms by which the 
mutated huntingtin causes the disease remain unclear.  
In order to understand the molecular processes causing the brain damage in 
HD patients, a vast array of genetically-modified cell and animal models has 
been developed. The organisms used to model various aspects of the disease 
includes worms (Caenorhabditis elegans), fruitflies (Drosophila 
melangaster), mice, rats, sheep and, more recently, pigs and monkeys (Pouladi 
et al., 2013). However, animal models have their limits in resembling human 
brain development and pathology because of profound morphological and 
physiological differences that distinguish human brain from other animal 
species, differences that are less marked in other organ systems (Muzio and 
Consalez, 2013). Moreover, many of the observations of the HD molecular 
features were based on experiments done in non-human cells transfected with 
cDNAs encoding mutant HTT and in primary human cell lines like fibroblasts 
and lymphoblasts from HD patients (Ross and Tabrizi, 2011; Seong et al., 
2005). However, these models present limitations due to the differences 
between human and non-human cells and between non-neuronal and neuronal 
cells, thus preventing to find a good target for new drugs in HD patients. 
The discovery of induced pluripotent stem cell (iPSC) technology offer the 
possibility to generate patient-specific iPS cells and to enable the development 
of in vitro HD models that more accurately reflect the human disease (Golas 
and Sander, 2016). iPSC’s from HD patients can be propagated indefinitely 
and differentiated into any cell type in the human body even functional 
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neuronal cells (Hargus et al., 2014). This cell model can be used to conduct 
detailed studies of the disease mechanisms, cell therapy development, or the 
screening of new drug candidates. 
Human neuronal cells carrying the mutation can become a powerful tool able 
to overcome some of the limitations of in vitro modeling of neurodegenerative 
disease (Ma et al., 2012; Jeon et al., 2012). 
The main focus of this project was to obtain neuronal cell lines starting from 
the patient’s fibroblasts using the iPSC technology. The neural cell lines 
obtained with this protocol will be used to study the disease development and 
the impairment of metabolic pathways as well as to find lead compounds able 
to improve the HD phenotype. 
To achieve this objective, we collected fibroblast from patients carrying 
mutation of different length on the HTT gene. As shown in this thesis, we 
succeed in reprogramming the fibroblast obtained from two JHD patients, one 
adult HD patient and one healthy donor into iPSC. Neural stem cells obtained 
from the precursor differentiation were then analyzed at morphological and 
molecular level to underline functional and biochemical differences linked 
with the mutation. Moreover, we have started to study the gene expression of 
both iPSC and iPSC derived neural stem cells and we have discovered that 
proteins involved in differentiation of neural stem cell to cerebral cortex 
neurons and in the glucose transport are differentially expressed in the HD 
model with respect to the control, indicating an impairment of both the neural 





3.1 Obtaining human dermal fibroblasts from healthy donors and 
HD patients. 
 
An important part of this project concerned the recruitment of healthy donors 




















 Table 3.1 Personal features of subjects enrolled in the project. 
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In table 1 the age at the time of the biopsy and the gender of both HD and 
control subjects are shown. The length of CAG repeats in HTT alleles and the 
Total Functional Capacity Score (TFC) are reported only for the HD patients. 
TFC is a standardized scale used to assess capacity to work, handle finances, 
perform domestic chores and self-care tasks, and live independently. The TFC 






















HD8YRS HD 256.05 HD 438 LANI FF113 
c) 
d) 
Figure 3.1 a) cartoon of a skin biopsy b) Cells coming out from a skin 
biopsy after 12 days of incubation at 37°C in enriched DMEM medium; 
Phase contrast images: c) Fibroblasts growing out from the edges of each 






Two of the HD patients presented a juvenile onset of the disease and one of 
them an infantile onset. From the skin biopsy, human primary dermal 
fibroblasts were isolated and expanded for further experiments (fig. 3.1). 
Comparing the growth rate of dermal fibroblasts, a correlation was found with 
the TFC at the time of biopsy. No significant correlation was found between 























































HD438(CAG 64 TFC 5)
HD256.01(CAG 44 TFC 3)
HD508.01(CAG 43TFC 3)
HD471.02(CAG 47 TFC 4)
HD8YRS(CAG 85 TFC ?)
HD654.01(CAG 42 TFC 11)
HD 256,05(CAG 43 TFC 13)
HD4503(CAG 43 TFC 12)

































Figure 3.3 A) Proliferation plot of primary dermal fibroblasts obtained from 
the skin biopsies of control and HD subjects with different TFC (total 
functional capacity score) and CAG repeat stretch. B) Comparison of 
proliferation plots of fibroblasts grouped for TFC and CAG repeat expansion. 
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3.2 Induced pluripotent stem cells from wild-type and HD 
fibroblasts show both stemness and pluripotency features.  
 
Primary skin fibroblasts from a healthy donor and three HD patients (two with 
a juvenile and one with an adult onset of the disease) were reprogrammed into 
induced pluripotent stem cells. The nucleofection was performed using 
Nucleofector4D with a protocol optimized in our lab (fig. 3.4-b). A mix of 
pCXLE based episomal vectors carrying the four human reprogramming 
factors, Oct4, Klf4, Sox2 and Myc and other stamness genes (Lin28, sh-p53) 
were introduced directly to the nuclei (Okita et al., 2011). From reprogrammed 
fibroblasts, we were able to select and expand iPSC-like colonies presenting a 
flat morphology and defined borders (fig. 3.4-c and d). Several clones, that 
resulted karyotypically normal (fig. 3.4-e), were then characterized for their 
stemness and pluripotency in order to be validated as bona fide iPSC’s. 
Immunostaining analysis against Oct4 and Tra-1-60 demonstrated that the 
tested clones express both stemness markers (fig. 3.5-a). Real-Time PCR 
analysis confirmed the expression of several endogenous stemness markers in 
all iPSCs lines (OCT4, KLF4, LIN28, SOX2 and MYC), six divisions after the 
first isolation of the single clone (fig. 3.5-b). Pluripotency of the new iPSCs 
lines was verified in vitro through embryoid bodies (EBs) formation assay and 
in vivo through teratoma formation assay. When cultured in the absence of 






































FF113 LANI HD 438 HD 256 
c) 
d) 
Figure 3.4 Reprogramming experiments protocol. a) Maps of episomal 
vectors used for reprogramming experiments. b) Time-line of reprogramming 
procedures. Phase contrast images: c) The first iPSC’s colonies of each cell 
line growing up in the reprogramming dish d) Isolated iPSC’s  clones after 
six passages showing a typical flat morphology. E) Karyogram of iPSC’s 


























































































Figure 3.5 a) Immunofluorescence analysis against Oct4 and Tra-1-60 on LANI(ctrl); 
FF113 (ctrl); HD 438 (CAG 64); HD 256.05(CAG 43) and HD 8YRS (CAG 85) iPSCs 
clones showed the expression of both stemness markers, indicating a reactivation of 
endogenous stemness genes after reprogramming. RED = Tra-1-60; GREEN = Oct4: 
BLUE = Nuclei b) Real-time PCR analysis confirmed the expression of several 
endogenous markers (KFL4; LIN28; MYC; SOX2; OCT4) in iPSC lines. All results 





Pluripotent stem cells within embryoid bodies undergo differentiation in the 
three germ lineages – endoderm, ectoderm, and mesoderm. Real Time PCR 
analysis showed induction of ectoderm, mesoderm and endoderm markers 
(fig.3.5-b). When injected subcutaneously in immunocompromised mice 
iPSC’s are able to generate teratomas comprising tissue representatives of all 
three embryonic germ layers (ectoderm, mesoderm and endoderm), thus 












































ECTO MESO ENDO 
HD8YRS FF113 LANI HD 438 HD 256 
Figure 3.5 a) Phase image of Embryoid bodies (EB’s) formed 14 days 
after, growing iPSC from each line in floating conditions in KOSR medium 
b) Real-time PCR analysis carried on embryoid bodies confirmed the 
expression of all the three germ layers for both mutated and control cell 
lines, indicating pluripotency properties of cells. ECTO = ectoderm; 


















































FF113 LANI   HD8YRS HD256.05 HD438  
a) 
b) 
Figure 3.6 a) Teratoma formed after subcutaneous injection of iPSC’s 
in immunocompromised mice. b) Histological analysis of teratomas 
obtained through teratoma formation assays showed the presence of 
tissue deriving from all the embryonic layers, confirming once more 
pluripotency capability. of these cell lines. 
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3.3 Differentiation of JHD and control iPSCs in neurospheres of 
Neural Precursor Cells presenting a correct morphology and self-
renewal capability. 
 
A new protocol for differentiation of iPSCs-derived embryoid bodies in Neural 
Precursor Cells (NPCs) was optimized in our lab. iPSC derived NPCs can be 
cultured as floating neurospheres, expanded and differentiated as “natural” 



















Figure 3.7 a) Scheme of neurosphere differentiation protocols from EBs. 
b) Self-renewal and proliferation analysis of HD 8yrs and FF113 
neurospheres. c) Neurospheres obteined from HD8yrs(JHD) and d) 








Briefly, this protocol includes an initial phase of embryoid bodies formation 
and neural-ectodermal cells enrichment through specific conditions. With this 
new method of differentiation there is no need to use any molecule to drive or 
induce iPSC’s to the neuronal lineage. Conversely, the iPSC’s are grown and 
maintained in specific conditions that mimic the early embryonic stages in 
vivo. This protocol is based on the spontaneous differentiation into NPCs by 
using culture mediums able to select only cells with neural precursor 
characteristics (Vescovi et al., 1999). Neurospheres were presented with the 
characteristic floating morphology and showed self-renewal properties (fig. 
3.7). 
   
3.4 iPSC derived neurospheres from HD and healthy individuals 
were able to differentiate in neurons, astroglia and 
oligodendrocytes. 
 
Neurospheres, which have multipotent properties, can differentiate in all the 
three neural lineages (neurons, astroglia and oligodendrocytes), just by adding 
differentiative stimuli such as: cell adhesion matrix, bovine serum and removal 
of essential growth factors (FGF2 and EGF). Indeed, our neurospheres derived 
from both FF113 and HD8YRS iPSC lines were capable to spontaneously 
differentiate in different subtypes of neuronal and glial cells. We performed an 
immunofluorescence analysis 10, 17, 24 and 31 days after the differentiation 
to detect specific neuronal markers of cells originated from the spheres. We 
used anti-GFAP antibody to label glia cells, anti-Tuj 1 (neuron-specific class 
































































































We observed that the ratio between the number of neurons (TuJ1+ cells) and 
the total cells at 10 days after the differentiation was lower in the HD8YRS 
sample (8,7%) with respect to the FF113 control (12,2%). Conversely, no 
significant difference was detected between the two cell lines at 17, 24 or 31 
days after the differentiation. The highest number of neurons (TUJ1+) was 
found, in both the cells lines, 24 days after differentiation (24 DIV) (⁓20%) 
(fig. 3.8). We used also anti-GABA antibody to identify gabaergic neurons, 
and anti-GALC (Galactocerebrsoside) to identify oligodendrocites. As shown, 
in (fig. 3.9) we did not observe differences in the percentage of gaba, or galc 
positive cells in the two compared samples (FF113 and HD8YRS). 
 
Figure 3.8 Immunofluorescence analysis 10; 17; 24 and 31 days after spontaneous 
differentiated neurospheres showed the presence of both neuronal and glial cells from 
mutated and control cells at different time points. RED = β-Tubulin-III; GREEN = 
GFAP; BLUE = Nuclei. A) HD8YRS B) FF113 C) Neuronal count performed on 
HD8YRS and FF113 differentiation experiment showed a significant difference in 
percentage of TuJ1+ only in the first stages of differentiation (10 Days after 



























































Figure 3.9 a) Immunofluorescence analysis 24 days after spontaneous 
differentiated neurospheres showed the presence of Gaba-ergic and 
Glutaminergic neurons (data non shown for glutaminergic neurons) and 
oligodendrocite  RED = oligodendrocytes; GREEN = gabaergic neurons; 
BLUE = Nuclei.  b) Count performed on HD8YRS and FF113 differentiation 
experiment showed no significant difference in percentage of GABA or GALC 
24 days after differentiation.  
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3.5 iPSC HD-derived neurospheres exhibit impaired brain 
development processes when compared with iPSC-derived 
neurospheres from healthy individuals. 
 
The list of differentially expressed genes between iPSC HD derived 
neurospheres, compared with iPSC-derived neurospheres from healthy 
individuals, were subjected to in silico functional enrichment analysis. In 
contrast, the former group exhibited a (estimated) reduced activity of the 
following pathways, when compared to the expression profiles of the iPSC-
derived neurospheres from healthy individuals: Synaptic Long Term 
Potentiation (z-score = -0.816) and CREB Signaling in Neurons (z-score = -
1.633). Other important pathways resulted significantly altered without the 
possibility to computationally estimate their activation states. These are 
reported in table 3.2.  
In line with these pathways, we found that an array of biological functions 
related to the CNS were significantly considered to work at a reduced activity 
in HD neurospheres: development of interneurons (p-value = 1,16E-03, z-score 
= -1), development of neurons (p-value =5.29E-11, z-score = -1.265), cell 
movement/migration of neurons (p-value = 3,00E-05 and p-value = 5,87E-05, 
z-score = -1.373 and z-score = -1,694) and proliferation of neuronal cells (p-
value = 4,27E-05, z-score = -1,392). More macroscopically, we found that the 
formation of brain/forebrain (p-value = 4,98E-04 and p-value = 4,34E-06, z-
score = -1,103, z-score = -0,357) were reduced activities in HD neurospheres. 
(table 3.3). In fig.3.10 and 3.11 can be also be observed that respect to iPSC-
derived neurospheres from healthy individuals in HD-derived neurospheres 
there is an impaired expression of the genes involved in the cortex 
differentiation and the two principal glucose transporters in the brain, glut1 (p-
value 0.008; fold change 1.78) and glut3 (p-value 0.06; fold change -2.41674). 
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Ingenuity Canonical Pathways -log(p-value) Ratio z-score Molecules 
Mitotic Roles of Polo-Like Kinase 3,39E00 1,06E-01 -1,342 7 
Cell Cycle: G2/M DNA Damage  2,48E00 1,02E-01 1,342 5 
Wnt/β-catenin Signaling 1,62E00 4,73E-02 1,890 8 
Signaling by Rho Family GTPases 1,48E00 4,05E-02 0,333 10 
Synaptic Long Term Potentiation 1,42E00 0,05 -0,816 6 
Glioma Signaling 1,11E00 4,55E-02 -0,447 6 
Neuropathic Pain Signaling  1,06E00 4,39E-02 -1,342 5 
CREB Signaling in Neurons 1,06E00 3,8E-02 -1,633 7 
 
Functions Functions Annotation p-Value z-score Molecules 
organismal  organismal death 1,70E-08 3,854 119 
perinatal death perinatal death 2,39E-05 2,867 35 
cognitive imp. cognitive impairment 1,54E-04 1,982 27 
Apoptosis Apoptosis 1,04E-04 1,702 111 
Congenital malformation of brain 1,14E-04 1,664 21 
cell death cell death 1,25E-04 1,183 137 
Interphase Interphase 4,06E-04 0,872 35 
Necrosis Necrosis 5,99E-06 0,450 118 
Development of cerebral cortex 1,28E-05 0,391 15 
Formation formation of brain 4,34E-06 -0,357 34 
Development central nervous system 3,88E-07 -0,607 43 
Development development of gap junctions 8,73E-04 -0,980 15 
Development development of interneurons 1,16E-03 -1,000 4 
Formation formation of forebrain 4,98E-04 -1,103 16 
Quantity quantity of interneurons 7,09E-04 -1,187 5 
Formation intercellular junctions 9,40E-04 -1,226 17 
Development development of neurons 5,29E-11 -1,265 59 
cell movement cell movement of neurons 3,00E-05 -1,373 19 
Proliferation proliferation of neuronal cells 4,27E-05 -1,392 33 
Migration migration of neurons 5,87E-05 -1,694 18 





Transcription Transcription 1,12E-04 -1,834 88 
Transcription transcription of RNA 8,76E-05 -1,875 81 
Locomotion Lo comotion 1,01E-03 -2,219 20 
cell viability cell viability 1,68E-06 -4,082 70 
Survival cell survival 4,23E-06 -4,263 72 
 
Table 3.3 In silico functional enrichment analysis. A list of differentially 
significantly activated biological (a) pathways b) functions) related to the CNS 
between iPSC derived neurospheres from HD patients, compared with iPSC-
derived neurospheres from healthy individuals. 
 
 
                          
 
Figure 3.10 Afymetrics human transcriptome gene chip analysis Fold change 
HD spheres Vs Control spheres: iPSC derived neurospheres show an impaired 
gene expression a) of molecules involved in the cortex differentiation. b) the 















































































































































4. Discussion and conclusions 
 
Huntington disease (HD) is a devastating, progressive autosomal-dominant 
neurodegenerative disease, caused by abnormal expansion of CAG repeats in 
the huntingtin gene, translated into a polyglutamine (polyQ) stretch in the HTT 
protein. The normal function of HTT, and the molecular mechanisms that 
contribute to the disease pathogenesis, are still unclear and currently there is 
no treatment known to cure or slow the disease progression. Typically, the 
symptoms consist of motor, cognitive, and psychiatric disorders (Banno et al., 
2017). Before that Yamanaka and coworkers generated induced pluripotent 
stem cells (iPSC), directly from fibroblast cultures (Takahashi and Yamanaka, 
2006), animal models and immortalized cell systems were the most used 
models of human diseases mechanisms and therapeutic development in HD.  
These models helped in understanding many of the impaired pathways in HD 
but have their limitations. Apart from man, no known animal naturally 
develops HD. Human conditions are not always reflected in transgenic animal 
models because of species differences and immortalized cells are artificially 
manipulated. 
Induced pluripotent stem cells (iPSCs) generated from somatic cells of patients 
can be used to model different human diseases. The disease-specific iPSCs can 
be differentiated into relevant cell-types affected in HD, holding a great 
potential for disease modeling and drug screening (Jang et al., 2014). 
In the present study, we have obtained dermal fibroblasts from 16 HD patients, 
and 6 healthy controls. The patients and the control subject were recruited in 
base of their CAG repeat expansion, TFC, and age at onset of the disease, with 
two of them presenting a juvenile onset. 
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We succeed in reprogramming into induced pluripotent stem cells the 
fibroblasts from a young adult healthy control, a young subject with 43 CAG 
repeats, in an early stage of the disease (TFC 13) and two JHD patients. The 
youngest patient (85 CAG repeats) presented an infantile onset of the disease, 
with appearance of the first signs of the disease at the age of 4 (the skin biopsy 
collected at age of 8). The other JHD patient displays 64 CAG repeats, 
presenting an adolescent onset. At the time of the biopsy, she was 25 years old 
displaying a low Total Functional Capacity Score (TFC=5), (table 3.1). The 
iPSC obtained, retained the original mutation in the HTT gene and presented a 
normal karyotype after reprogrammation. The test performed in vitro and in 
vivo to evaluate their stemness and pluripotency gave positive results. Indeed, 
the iPSCs produced in our laboratory are able to spontaneously generate 
embryoid bodies, expressing the three germ lineages: endoderm, ectoderm, and 
mesoderm and teratomas once injected subcutaneously in 
immunocompromised mice.  
Juvenile Huntington disease (JHD) is defined by the onset of symptoms before 
21 years of age. People with JHD have larger CAG repeats in the HTT gene 
compared to the individuals that will develop HD symptoms as adults. There 
is similarity between the pathology seen in HD and JHD. However, symptoms 
of juvenile and adult HD (AHD) subjects differ from each other in most of the 
cases. Behavioral and cognitive problems are the most common symptoms 
among JHD and it is well recognized that declining school performance can be 
a significant feature of JHD with speech and language problems that may occur 
early in the course of the illness (Bruyn, 1968; Ribai et al., 2007; Yoon et al., 
2006).  It is not rare in JHD that a child develops HD before his parent and the 
theory that JHD is more aggressive and presents a shorter disease duration that 
adult HD is widely held (Senaca et al., 2004). In a recent study gene-expanded 
children (CAG repeats >39) had a significantly smaller mean brain size 
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compared with controls, suggesting a specific deficit in brain growth, rather 
than a global growth abnormality. These findings suggest that abnormal HTT 
may have a direct effect on brain development and led to the speculation that 
this phenomenon is more pronounced in JHD (Lee et al., 2012; Querrell et. al, 
2013).  Most of the HD symptoms are related to a neuronal cell loss in the brain 
and it would be helpful to study molecular events taking place in first stages of 
neural development.  
 For this reason, iPS from cells from both JHD (85CAG) and healthy control, 
were differentiated into neurospheres of neural precursors (NPCs). NPCs were 
obtained using a new protocol, that consist in culturing iPSC-derived embryoid 
bodies and then selecting neural precursor with a selective NPCs medium that 
allowed the survival of cells with acquired neural properties. These “induced” 
NPCs demonstrated to have the same properties of “natural” NPCs: they grew 
as floating spheres, known as neurospheres capable of self-renewal and 
proliferate in vitro; their growth is dependent upon the presence of specific 
growth factor, such as bFGF and EGF (data not shown) and they can 
differentiate in all of three neural lineages (neurons, astroglia and 
oligodendrocytes). This new protocol may represent a valid model to study 
brain development in vitro. The iPSC derived neurospheres grow as 3D 
structures mimicking the natural conditions (Muniany et al., 2016). 
Spontaneous differentiation of the spheres from AHD and JHD compared with 
control ones, can give a lot of information about the metabolic and 
development impairments during neurogenesis (Kang et al., 2007). Neuronal 
and glial cells generated by this new approach can offer a better understanding 
of the disease features (Szlachcic et al., 2017). They can also become a 
valuable tool to test the efficiency of potential new drugs (Zhang et al., 2016).   
Gene expression profiling was performed on iPSC HD-derived neurospheres 
using GeneChip Human Transcriptome Array 2.0.  iPSC HD-derived 
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neurospheres exhibit an impaired brain development processes when 
compared with iPSC-derived neurospheres from healthy individuals.  Several 
genes involved in the cortex differentiation resulted hypo-expressed in JHD 
spheres (fig. 3.10). Studies on transgenic rodents and postmortem HD brains 
revealed that cortical atrophy and loss of CPNs is a neuropathological hallmark 
of HD. HD is characterized by dysregulated information flow through the 
cortico-striato-cortical pathway. This problem, moreover, emerges early in the 
course of HD, even before some neurological signs are present, suggesting a 
key role in the development and subsequent progression of the HD behavioral 
phenotype. Further research on alterations in cortical processing in HD, 
including the contribution of thalamic inputs and cortical interneurons, is 
emerging as fertile ground for further insight into the neuronal mechanisms 
underlying HD and for the development of effective therapeutic strategies. 
(Estrada-Sánchez and Rebec, 2013).  
The experiments also showed that GLUT3 (encoded by the SCL2A3 gene) is 
down- regulated in the HD adult neurosphere with respect to the control 
neurosphere (fold=-2.41, p<0.05) whereas GLUT1 (encoded by SLC2A1 
gene) is up-regulated in the HD neurospheres with respect to control 
neurospheres (fold=1.78, p<0.05) (figure 3.10). GLUTs are transporter 
molecules that allow glucose to move from blood to brain (Olson and Pessin 
1996). All mammalian cells contain one or more members of this family. The 
human genome encodes 14 different GLUT proteins that facilitate the passage 
of sugars (e.g., glucose, fructose) across cell and intracellular membranes. The 
most highly expressed GLUTs in the brain are GLUT1 and GLUT3. Glucose 
is then taken up into astrocytes GLUT1, and into neurons by GLUT3.  GLUT3 
is highly and specifically expressed in neurons. It has both higher glucose 
affinity and transport capacity than GLUT1, and its expression increases 
concomitantly with the maturation of synaptic connections (Simpson et al. 
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2008). In recent papers, an early glucose hypo-metabolism was already shown 
in HD patients (Squitieri and Ciarmello 2010). Several evidences connect the 
impairment of the energetic metabolism to a defective transportation of 
glucose in the brain (Adanyeguh et al. 2015). Even if our results have been 
obtained on neurospheres i.e. neuronal stem cells, and not in differentiated 
cells, they demonstrate that glucose transport is impaired in the HD patients 
cells. Finding a way to restore the brain glucose uptake or providing efficient 
alternative sources to glucose can offer future therapeutic strategies to contrast 
the disease (Morea et al., 2017). This indicates that this analysis can give a 
great help in trying to understand metabolic impairments during development.  
Since one of the properties that NPCs is the ability to differentiate in all neural 
lineages, we performed a spontaneous differentiation of neurospheres from the 
JHD patient and the control donor. Differentiation assay confirmed that they 
possessed this potentiality, being capable subtypes of neuronal and glial cells. 
Immunofluorescence analysis after 10, 17, 24 and 31 days from the 
differentiation demonstrated that FF113 and HD8YRS spheres were able to   
spontaneously differentiate in different cells positive for different markers of 
glial or neuronal cell sub-types. We confirmed that neurospheres derived from 
the HD iPSC’s differentiate in glutaminergic (data not shown) and gabaergic 
neurons and in oligodentrocytes. These three types of cells are known to be 
susceptible to degeneration in HD. 
This study aimed to produce a valid model of the Huntington disease. We are 
confident that this novel in vitro model will permit us to have a closer view to 
neuronal development networks by morphologically and physiological studies 
on the cell types obtained from the neuropheres of NPC. 
We are also interested in studying the basis and the mechanisms that bring to 
impaired metabolism pathways in HD such as glucose transportation and 
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calcium homeostasis and to offer this results to the scientific community in 
order be able to reverse the disorders caused from this impaired functions. 
 
5. Materials and methods  
  
5.1 Skin biopsies collection  
 
Dermal skin biopsies were collected using a monouse biopsy punch. Skin 
fragments were then handly cutted in smaller fragment and plated on a 35mm 
tissue-culture dish with fetal bovine serum (FBS – Sigma Aldrich) at 37°C 
5%CO2 over-night. The day after, dermal fragments were transferred in 
Dulbecco’s Modified Eagle Medium (DMEM) High Glucose (Sigma Aldrich) 
supplemented with 20% FBS (Sigma Aldrich),  
2mM L-Glutamine (Sigma-Aldrich), 100U/ml Penicillin Streptomicin (Sigma 
Aldrich) and 1X Non-essential Amino Acids (Sigma Aldrich) and cultured 
until fibroblasts, spreading out from skin fragments, reached confluency. Then 
cells were treated as a normal primary fibroblast culture (see section 5.2).  
   
5.2 Primary skin fibroblasts culture.  
 
All primary skin fibroblasts were cultured in DMEM High Glucose 
supplemented with 20% FBS, 2mM L-Glutamine, 100U/ml Penicillin-





5.3 Episomal vectors  
 
For cell reprogramming was used a mix of three pCXLE-based episomal 
vectors previously described in Okita et al. (Okita et al., 2011).  
Episomal vectors has been bought as glycerol-stock from Addgene (plasmids 
#27077, #27078 and #27080), were amplified and plasmids were extracted 
with Endo-Free Maxi Kit for low-copy number plasmids (Qiagen) according 
to manufactor instructions, then were verified through restriction analysis.  
 
5.4 iPSCs production and culture  
 
For reprogramming experiments, 300,000/reaction JS and control fibroblasts 
were nucleofected using the optimized pulse/buffer condition with 0.5 and 3μg 
of the previously described mix of episomal vectors (Okita et al., 2011) with 
the standard nucleofection protocol given by the producer. Briefly, after 
nucleofection, cells were plated in fibroblasts medium without antibiotics 
overnight and transferred in normal culture conditions the day after. Six days 
after nucleofection, 140,000 fibroblasts were seeded on a 100mm dish 
previously coated with Matrigel (Corning). The next day, medium was 
changed with Nutristem-XF (Biological Science). After 25-40 days from 
nucleofection, first iPSC colonies were manually picked, fragmented and 
individually passaged in a 24-well plate (passage I, pI) coated with Matrigel. 
From each reprogramming experiment, at least 3-5 iPSC clones, selected by 
morphology (flat and uniform colonies with defined borders), were expanded 
from pI. From pII, established iPSC lines were maintained in 6well plate and 
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passaged weekly with 1 mg/ml dispase (Gibco) in DMEM F-12 (Sigma-
Aldrich).  
  
5.5 Embryoid bodies formation assay.  
 
iPSCs from an entire 6-well dish were detached using 1mg/ml dispase and then 
plated in a petri dish in floating condition. Nutristem-XF medium was then 
gradually switched to KOSR medium (DMEM F-12, 20% Knock-out serum 
replacement (Gibco), 0.1mM β-mercaptoethanol, 1X NEAA, 50U/ml 
Penicillin-Spreptomicin, 2mM L-glutamine) in 3 days and cells mantained in 
culture for 14 days.   
  
5.6 Teratoma formation assay.  
 
iPSCs from an entire 6-well dish were detached using 1mg/ml dispase, 
resuspended in 100ml of Matrigel and injected subcutaneously in the hind leg 
of immunocompromised mice. Teratoma growth was monitored up to 80 days 
after injection; then animals were sacrified and tumors hystologically 
analyzed.  
  
5.7 Neurospheres production, culture and growth curves.  
 
Embryoid bodies were produced as described in section 4.6. Unlike the classic 
embryoid bodies formation assay, cells were transferred at 37°C, 5% CO2, 5% 
O2 at day 5 after their production and maintained in these conditions for 52-
54 days. At the end of this period, as previously described in Vescovi et al. 
cells were cultured as “natural” neuroprecursors cell lines (NPCs): cultures 
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were harvested, mechanically dissociated, and replated under the same 
conditions at a density of 104 cells/cm2 every 7–10 days in the same growth 
medium (Vescovi et al., 1999). 
For growth curves, 250,000 cells were plated in growth medium in a 25cm2 
flask, harvested and counted every 7-10 days. Then 250,000 cells were replated 
and counted in the same way. At least 5 time-points in triplicate for each cell 
line were collected.   
   
5.8 Neurospheres differentiation assay.  
 
To study NPCs differentiation capacity, their multipotency was determined by 
in vitro differentiation tests, in which the simultaneous  presence  of 
neurons,  astrocytes  and oligodendrocytes was detected by 
immunocytochemical labeling (see section 5.10). Neurospheres were 
mechanically dissociated and cells were seeded on a cultrex layer (Cultrex® 
Basement Membrane Extract, Trevigen) and incubated at 5% O2, 5% CO2 and 
37°C for 3 days’ growth medium used during their routine culturing. Then 
culture medium was replaced with DMEM/F12 supplemented with 2% FBS, 
without growth factors. Cells differentiation was monitored at 10, 17, 24 and 
31 days after FBS addition.  
  
5.9 Immunostaining and immunofluorescence imaging  
 
5.9.1   Fibroblasts:  
Cells were fixed in ice-cold methanol at  
4°C for 5 minutes. Aspecific sites on fixed cells were blocked with 10% 
Bovine Serum Albumine (BSA – Sigma Aldrich), 1% Normal Goat Serum 
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(NGS – Sigma Aldrich) in 1X Phosphate Buffered Saline with Ca2+ and Mg2+ 
(PBS++ - Sigma Aldrich) and then cells were incubated at 4°C overnight with 
primary antibodies diluted in 5% BSA in 1X PBS++.   
 
    5.9.2iPSCs:  
Cells were fixed in 4% parafolmaldehyde for 20  
minutes at room temperature. Fixed cells were then permeabilized and blocked 
with 10% NGS, 1% BSA, 0.1% Triton X-100 for 45 minutes at room 
temperature and then incubated overnight at 4°C with primary antibodies 
diluted in 5% BSA.  
 
   5.9.3 Neural cells:  
Cells were fixed in 4% paraformaldehyde for 10 minutes at room temperature. 
Fixed cells were then permeabilized with 0.1% Triton X-100 for 10 minutes at 
room temperature and blocked with 10% NGS for 1 hour at room temperature. 
Cell were after incubated overnight at 4°C with primary antibodies diluted in 
blocking solution and then incubated with the proper fluorescent secondary 
antibodies for 1h at room temperature.  
Nuclei were labeled in every immunostaining with Hoechst 33342 (Life 
technologies).  
After staining, coverslips were mounted with Vectashield Antifade Munting 
Medium (VectorLabs)  
All immunofluorescence images were acquired using a Nikon C2 microscope 
with 10X (iPSCs), 20X (Neural cells), 40 and 60X (Fibroblasts) objectives and 
NIS Elements 1.49 program. For every group of experiments were used the 
same camera settings.   




5.10 Antibodies  
 
Primary antibodies: anti-Oct4 (1:100 – Life technologies), anti-Tra-1-60 
(1:100 – Life Technologies), anti-TuJ1 (1:400 – BioLegend), anti-GFAP 
(1:200 – GAKO), anti-GalC (1:200 – Merck Millipore), antiRabbit AlexaFluor 
488 (Invitrogen), anti-Mouse AlexaFluor 555 (Invitrogen), anti-Mouse HRP-
linked antibody (1:10000 – Amersham), anti-Rabbit HRP-linked antibody 
(1:10000 – Amersham).  
  
5.11 RNA extraction and quality evaluation  
 
Total RNAs were isolated using TRIzol reagent (Life Technologies) according 
to manufacturer’s instructions. RNAs quality was assessed by determining UV 
260/280 absorbance ratios at Nanodrop 1000 (Thermo Scientific) and 
examining RNA size distribution on RNA 6000 Nano LabChips (Agilent 
Technologies) processed on the Agilent 2100 Bioanalyzer using the total RNA 
electrophoresis program. Only RNAs with a RNA Integrity Number (RIN) ≥ 8 
were used for subsequent analysis.   
  
5.12 Reverse-transcription and Real-Time PCR  
 
Reverse transcription was performed using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to manufacturer’s 
instructions after digestion with DNAse I (Life Technologies).  
Real-Time PCR was performed in a 7900HT Fast Real-Time PCR system 
(Applied Biosystem). For each gene of interest, qRT-PCR was performed as 
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follows: each RNA sample was tested in duplicate and β‐Actin was used to 
normalize transcript abundance and calculations were performed with the delta 
Ct method. Statistical analyses were performed on three indipendent 
experiments.  
Sybr green reactions were performed using Power SYBR Green PCR Master 
Mix (Applied Biosystem) with this PCR program: denaturation 95°C for 10 
minutes; amplification 95°C for 10 seconds, 60°C for 10 seconds, 72°C for 30 
seconds all repeated for 50 cycles; final elongation 72°C for 7 minutes; final 
dissociation step 95°C for 15 seconds, 60°C for 15 seconds, 95°C for 15 
seconds.  
TaqMan reactions were carried out using TaqMan Universal PCR Master Mix 
(Applied Biosystem) and PCR were performed according to manufacturer’s 
instructions. 
Gene  Primer  
hOct4  
Totale  
Fwd: CCC CAG GGC CCC ATT TTG GTA CC  




Fwd: AGC CAT ATG GTA GCC TCA TGT CCG C  
Rev: TCA ATT CTG TGC CTC CGG GAG CAG  
GGT AGG  
hKfl4  
Totale  
Fwd: ACC CAT CCT TCC TGC CCG ATC AGA  
Rev: TTG GTA ATG GAG CGG CGG GAC TTG  
h-Myc  
Totale  
Fwd: GCG AAC CCA AGA CCC AGG CCT GCT CC  
Rev: CAG GGG GTC TGC TCG CAC CGT GAT G  
hSox2 
Totale  
Fwd: TTC ACA TGT CCC AGC ACT ACC AGA  
Rev: TCA CAT GTG TGA GAG GGG CAG TGT GC  
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β-ACTIN  Fwd: GGC ATC CTC ACC CTG AAG TA  
Rev: GGG GTG TTG AAG GTC TCA AA   
18S Fwd: GGC CCT GTA ATT GGA ATG AGT C  
Rev: CCA AGA TCC AAC TAC GAG CTT   
  
 Table 2 – TaqMan primers.  
Gene  Probe              
SOX17  Hs00751752_s1  
PAX6  Hs00240871_m1  
FOXA2  Hs00232764_m1  
NESTIN Hs04187831_g1  
T  Hs00610080_m1  
EOMES  Hs00172872_m1  
SOX1  Hs01057642_s1  
GATA4  Hs00171403_m1  
GFAP  Hs00157674_m1  
SLC  Hs00188193_m1  
FABP  Hs00361426_m1  
DLX2  Hs00269993_m1  
EN1  Hs00154977_m1  
FOXG1  Hs01850784_s1  
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HOXB4  Hs00256884_m1  
IRX3  Hs00735523_m1  
OTX2  Hs00222238_m1  
SOX2  Hs01053049_s1  
AXIN2  Hs00610344_m1  
βTubIII  Hs00801390_s1  
CycD2  Hs00153380_m1  
CycD1  Hs00765553_m1  
Myc  Hs00153408_m1  
βActin  Hs 99999903_m1  
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 5.15 Whole genome expression profiling and in silico functional 
enrichment analysis of iPSC HD-derived neurospheres compared 
with iPSC-derived neurospheres from healthy individuals. 
 
Gene expression profiling was performed using GeneChip Human 
Transcriptome Array 2.0 following the manufacturer’s instructions 
(Affymetrix, Santa Clara, CA). Briefly, on 100 ng of total RNA, a random 
priming method was used to generate cDNA from all RNA transcripts present 
in a sample. The cDNA was fragmented and labeled with biotin using terminal 
deoxynucleotidyl transferase (TdT) before hybridization in a GeneChip 
Hybridization Oven 645 (Affymetrix). Following hybridization and post-
hybridization washes, the arrays were scanned using the Affymetrix GeneChip 
Scanner 3000 7G to generate the raw data (CEL file). The quality control steps 
of the experiment were performed using Expression Console v1.3 
(Affymetrix).  
Expression data were analyzed with Partek Genomics Suite 6.6 and R-3.1.2. 
In particular, quality assessment and signal normalization were performed with 
Partek. Filtering and statistical analyses were carried out with R. Raw data 
were log-transformed and quantiles normalized. Probes not mapping to any 
Entrez gene were removed. In cases where several probe sets mapped to the 
same gene, the one exhibiting the highest variance was chosen for further 
analysis. Batch effects were removed by Partek’s batch effect removal 
algorithm. Sample distribution among groups was assessed using principal 
component analysis (PCA). Correction for multiple test was achieved by the 
Benjamini-Hochberg procedure. Statistical differences in gene expression 





5.16 Functional enrichment analysis. 
 
Function, and pathway analyses were conducted using Ingenuity Pathway 
Analysis (IPA; QIAGEN, Redwood City, CA; www.qiagen.com/ingenuity). 
The entire procedure was based on the prior calculation of the activation z-
scores, which infer the activation states of predicted transcriptional regulators, 
functions, and pathways. Inference of activating or inhibiting molecules or 
biological functions is based on confirmation by the literature of the results of 
our experiments. An enrichment score (Fisher’s exact test, P-value) was 
calculated to measure the overlap between observed and predicted regulated 
gene sets. We considered P-values < 0.05, positive z-scores (activation) and 
negative z-scores (inhibition), as significant. 
 
5.15 Statistical analysis.  
 
Results are shown as the mean and standard error of the mean from at least 
three independent repeated experiments Statistical analyses were carried out 
by analysis of variance. Statistical significance was evaluated by a 2-tailed 
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